COVID-19 and Rare Skin Diseases European Observational Study During an Epidemic

Medical and demographic data will be collected from the medical records of patients. The
data required will be specified in Appendix 1 (collection form). Patients will be
identified by their initials (first letter of their surname and first name); The study
will last for one year to cover the COVID-19 epidemic in France (which includes the areas
of mainland France and its overseas departments and territories) and in Europe, via the
ERN-Skin European Network.

The frequency of severe forms of COVID-19 will be calculated with a bilateral 95%
confidence interval using, as a numerator, the number of patients with a severe form of
COVID-19 and, as a denominator, the number of patients with a COVID-19 diagnosis
confirmed by PCR, chest scan, serological assay or by suggestive clinical signs during
the medical consultation. A severe form of COVID is defined as a case requiring
hospitalisation in an intensive care unit, requiring resuscitation, or resulting in
death.

Analysis of the impact of COVID-19 infection on rare skin diseases: complications,
potential comorbidity factors, impact on the management of chronic conditions (change in
treatment) and the experience of patients.

The results of the analysis may be compared with those obtained for other groups of
diseases. Gaining a better understanding of high-risk situations, as well as any
aggravation or protective factors, should enable us to issue recommendations adapted to
this kind of disease but that may also be useful for the general population. This type of
study may also provide "reassurance" to patients with rare diseases who have many
questions during this period of epidemic and heightened concern.